Amid Supply Concerns, EU Approves Gilead’s Remdesivir
Despite Controversy, Blockbuster Status Predicted
Europe has granted a conditional approval to Gilead’s drug, now named Veklury, costing €2,000 per treatment.
Europe has granted a conditional approval to Gilead’s drug, now named Veklury, costing €2,000 per treatment.